Results 291 to 300 of about 2,545,958 (345)

Remote spatial memory deficits in mouse models of neuropsychiatric disorders with immature dentate gyrus phenotype. [PDF]

Int J Neuropsychopharmacol
Shoji H, Hagihara H, Graef IA, Crabtree GR, Huang FL, Frankland PW, Miyakawa T.   +6 more
europepmc   +1 more source

Assessing a Mitochondrial Disease Treatment via a Novel Statistical Technique for Accelerometer Data

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Therapeutic development for mitochondrial diseases, rare genetic disorders with pathogenic defects of oxidative phosphorylation, is hindered by unsatisfactory outcome measures. To address this problem, we provide the first clinical application of a novel, bias‐adjusted outcome measure of acceleration across a range of subjects ...
Ian W. McKeague, Kristin Engelstad, Yue Ge, Amber Tucker, Shufang Li, Jasim Uddin, Ziwei Zhao, John L. P. Thompson, Michio Hirano   +8 more
wiley   +1 more source

SCN5A Cardiomyopathy: from Ion Channel Dysfunction To Clinical Disease. [PDF]

Curr Cardiol Rep
Heymans ABM, Bianchi L, Volders PGA, van der Crabben SN, Verdonschot JAJ.   +4 more
europepmc   +1 more source

Characteristics of Cerebral Palsy in the Midwestern US

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Cerebral palsy (CP) is the most common lifelong motor disability worldwide. Yet, data is limited on how CP manifests in the US. Our objective was to characterize and determine factors affecting functional outcomes in a large population of young people with CP in the Midwestern US.
Susie Kim, Kelsey Steffen, Lauren Gottschalk‐Henneberry, Jennifer Miros, Amy Robichaux‐Viehoever, Karen Taca, Bhooma R. Aravamuthan   +6 more
wiley   +1 more source

Knocking out genes to reveal drivers of natural selection on phenotypic traits: a study of the fitness consequences of albinism. [PDF]

Proc Biol Sci
Funk AT, Martin J, Clark M, Païta A, Jolly CJ, Shine R.   +5 more
europepmc   +1 more source

CSF Mitochondrial DNA: Biomarker of Body Composition and Energy Metabolism in Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Cerebrospinal fluid (CSF) cell‐free mitochondrial DNA (cf‐mtDNA) is a potential biomarker for Parkinson's disease (PD), but its clinical relevance remains unclear. We investigated associations between CSF cf‐mtDNA levels, body composition, nutritional status, and metabolic biomarkers in PD. Methods CSF cf‐mtDNA levels, defined as the
Yasuaki Mizutani, Tsuyoshi Nakai, Yasuhiro Maeda, Reiko Ohdake, Atsuhiro Higashi, Toshiki Maeda, Ryunosuke Nagao, Sayuri Shima, Kazuya Kawabata, Akihiro Ueda, Mizuki Ito, Hirohisa Watanabe   +11 more
wiley   +1 more source

Editorial: Abiotic stresses in field crops: response, impacts and management under climate change scenario

Frontiers in Sustainable Food Systems
Aliza Pradhan, Ashim Datta, Ashim Datta, Ashim Datta, Milan Kumar Lal, Mahesh Kumar, Md Khairul Alam, P. S. Basavaraj, Kamal Krishna Pal, Kamal Krishna Pal   +9 more
doaj   +1 more source

Identifying and Characterising a Chronic Kidney Disease Electronic-Phenotype Using Electronic Health Record-Derived Data: A Narrative Review of Strategies and Applications. [PDF]

Nephrology (Carlton)
Sparks C, Steinberg AG, Toussaint ND.
europepmc   +1 more source

Nerve Excitability in Asymptomatic Carriers and Amyotrophic Lateral Sclerosis Patients With C9orf72

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective We investigated the effects of C9orf72 mutation carriership on peripheral nerve excitability in asymptomatic individuals from families with a history of C9orf72 amyotrophic lateral sclerosis (ALS) and patients. Methods We included 47 asymptomatic individuals from families with a history of C9orf72 ALS, of whom 23 were carriers (C9 ...
Diederik J. L. Stikvoort García, H. Stephan Goedee, Leonard H. van den Berg, Boudewijn T. H. M. Sleutjes   +3 more
wiley   +1 more source

Development of a prognostic multiomic biomarker of progression-free survival in advanced non-small cell lung cancer patients treated with first line immunotherapy. [PDF]

Sci Rep
Singh A, Horng H, Roshkovan L, Hershman M, Cohen EA, Aggarwal C, Carpenter EL, Katz SI, Kontos D.   +8 more
europepmc   +1 more source